bleomycin

The patient subsequently received 3 cycles of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. This case highlights the importance of diagnostic adaptability, multidisciplinary care, and long-term follow-up in achieving successful outcomes for rare thoracic malignancies. Broader lessons include the value of pragmatic decision-making, judicious use of limited diagnostic tools, and structured follow-up strategies that can guide clinicians facing similar challenges in resource-limited environments.

We successfully established a TYST PDX model that retains tissue structure and protein expression signature of the patient's tumor tissue. Furthermore, this PDX model demonstrates high sensitivity to standard JEB chemotherapy and represents a valuable resource for translational research in pediatric germ cell tumors.

Measuring BLMH levels may help stratify patients and personalize ECT application; however, it is not the sole factor for response prediction. Future studies in clinical tumor samples are warranted to evaluate its predictive value and to develop integrated biomarker models.

ECT synergizes with PD-1 blockade to potentiate local and systemic antitumor immunity, overcoming immune resistance in poorly immunogenic tumors. These findings support further clinical development of ECT in combination with immune checkpoint inhibitors as a component of personalized cancer immunotherapy.

We have reported that EETs inhibit AEC senescence, alleviating bleomycin (BLM)-induced PF in mice...Inhibition of Spi1 significantly attenuated AEC senescence. Inhibition of Spi1 alleviated pulmonary fibrosis in aging mice.

This study investigates the radioprotective potential of MO leaf extract against DNA damage induced by bleomycin and X-irradiation...Furthermore, molecular docking and 200 ns molecular dynamics simulations revealed that kaempferol, a major MO constituent, exhibited strong binding affinity with the Keap1-Nrf2 complex, suggesting activation of antioxidant gene expression. Overall, the findings support MO's role as a natural, low-toxicity radioprotective agent and highlight the complementary value of computational approaches alongside cytogenetic assays in validating therapeutic potential.

We describe a 74-year-old woman with stage IIIB SD-YST who underwent complete surgical resection followed by cisplatin-etoposide chemotherapy, with bleomycin omitted due to frailty. This case underscores the potential for long-term remission in SD-YST with platinum-based therapy, even when standard regimens require modification for older or frail patients. It highlights the value of biomarker-guided treatment adjustments to optimize chemotherapy timing in rare ovarian malignancies.

A bleomycin-induced lung injury model was also used to assess the anti-inflammatory effects of G31P, with or without gefitinib, by quantitative reverse transcription polymerase chain reaction (qRT-PCR) and flow cytometry of inflammatory markers. CXCR1/2 antagonism by G31P attenuates chemotherapy-induced pulmonary inflammation and enhances the anti-tumor efficacy of gefitinib in NSCLC. These findings support the therapeutic potential of G31P as an adjuvant to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) to improve clinical outcomes by limiting inflammation.

Here, we observed elevated AR expression and activity in the serum of patients with IPF and in the lungs of mice and rats with bleomycin - induced pulmonary fibrosis. Our findings indicate that AR plays a crucial role in pulmonary fibrosis by activating ERK-MYC signaling, promoting the expression of FASN and ACC1, enhancing fatty acid synthesis, and inducing macrophage M2 polarization. Notably, Epalrestat-an aldose reductase inhibitor approved by the Food and Drug Administration (FDA) for the treatment of diabetic neuropathy-exhibits potent antifibrotic effects in preclinical models, which supports its immediate clinical applicability for the repurposing of IPF treatment.

Pre-treatment biomarker levels were associated with greater KS tumor burden but not with KS response to chemotherapy + ART in people with advanced AIDS-KS. Differential levels of several serum biomarkers were noted on treatment in progressors and non-progressors, suggesting that increased tumor burden was associated with higher levels of inflammation and immune activation.

SQAP sensitized series of chemotherapeutic agents including doxorubicin, carboplatin, bleomycin, camptothecin, etoposide, methyl methanesulfonate, cisplatin, mitomycin C, and Taxol in canine tumor cells and V79 cells. These results suggest that broad inhibition of DNA repair may play a role in SQAP induced radiosensitization and chemosensitization.

Here, we will discuss the impact of diverse risk factors, including anticancer agents such as bleomycin and methotrexate; mineral silica; and metals like arsenic, aluminium and copper, which have been identified as potential triggers of pulmonary fibrosis. This review will also discuss the role of natural phytocompounds, including steroidal saponin, stilbenoid polyphenol resveratrol, safflomin of Carthamus tinctorius or safflower yellow, along with several genetic modulation approaches in addressing IPF. Finally, we examine the aspects and associations of IPF and SARS-CoV-2 to better understand disease severity, causes, and associated comorbidities.